The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

UNIPHYLLIN Continus 400 mg Prolonged-Release Tablets

Ennogen Healthcare (Europe) LimitedPA23369/003/003

Main Information

Trade NameUNIPHYLLIN Continus 400 mg Prolonged-Release Tablets
Active SubstancesTheophylline
Dosage FormProlonged-release tablet
Licence HolderEnnogen Healthcare (Europe) Limited
Licence NumberPA23369/003/003

Group Information

ATC CodeR03DA Xanthines
R03DA04 theophylline


License statusAuthorised
Licence Issued20/06/1983
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back